A newly released market report on November 26, 2025 indicates that the global oncolytic virus CDMO services market is entering a phase of accelerated growth. According to the report, the market is projected to expand from approximately USD 420 million in 2025 to around USD 1.734 billion by 2035, representing a compound annual growth rate (CAGR) of about 15.25% over the next decade .
Oncolytic virus therapy has emerged as a promising approach in cancer treatment by genetically engineering viruses to selectively infect and destroy tumor cells while stimulating anti-tumor immune responses. As more oncolytic virus candidates advance into clinical development, demand for specialized CDMO services continues to rise.
.jpg "Photo_by_Trnava_University_on_Unsplash_(2).jpg")
Photo by Trnava University on Unsplash
The report highlights that key service areas driving this market include viral vector manufacturing, upstream cell expansion, large-scale aseptic production, and quality control and analytical testing. CDMO companies with strong viral process development capabilities and GMP manufacturing infrastructure are expected to benefit significantly from this trend .
Market analysts note that the growth of the oncolytic virus CDMO sector is primarily supported by increasing global investment in oncology research, rising acceptance of novel gene and viral therapies, and growing reliance on outsourcing by emerging biotechnology companies. As more products move into late-stage clinical development and commercialization, regulatory and manufacturing requirements will also continue to intensify.
.jpg "Photo_by_Sangharsh_Lohakare_on_Unsplash_(2).jpg")
Photo by Sangharsh Lohakare on Unsplash
The report underscores that virus-related CDMO services are evolving from a supporting function into a core component of the cell and gene therapy value chain, with long-term strategic importance for the future of oncology innovation.
Source: GlobeNewswire, Oncolytic Virus CDMO Services Market to Reach USD 1,734.41 Million at 15.25% CAGR by 2035, November 26, 2025.
86 198 5711 6962 
info@hillgene.com 
English
